BMT CTN 1302: A Multicenter Phase II, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
ID Number 15-1389Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
Multiple Myeloma is a cancer of the blood that begins in the bone marrow, a cancer that is currently incurable and even interventions that work may stop working after some time. This recurrence of cancer is known as relapse. Allogeneic Stem Cell Transplantation (ASCT) is an intervention for cancers of the blood such as Multiple Myeloma. For transplant to work, doctors must combine the transplant with novel drugs that optimize the anti-cancer effects of transplant. These drugs reduce the risk of disease relapse long enough for the donor graft to learn to fight your cancer to take effect. This is called the "graft versus tumor effect".
You may qualify to take part in this research study because you are between the ages of 18 to 65, you have a closely matched related or unrelated peripheral blood stem cell donor, and you have high risk multiple myeloma and/or your Multiple Myeloma returned after an autologous transplant.
Recruiting Patients: Yes